The mission of the Cancer Risk and Disparities Program is to support research that will lead to a reduction of cancer risk and disparities across society. To achieve this goal, the Program has the following four specific aims: 1. Understand the individual, psychosocial, organizational and community-level factors that determine differences in cancer risk across the life course and population groups. 2. Develop, test and evaluate interventions to reduce cancer risk across the life course and population groups. 3. Advance the science of communication and knowledge translation to promote dissemination of evidence-based interventions to reduce cancer risk. 4. Examine causes of disparities in cancer risk and incidence and Identify interventions to redress these disparities. The Program was initially funded in 2000 when the Dana-Farber/Harvard Cancer Center was established as a consortium Center, and received a merit score of """"""""excellent to outstanding"""""""" at the time of the last renewal in 2005. The Program Is led by L. Frazier(DFCI). There are two Co-Leaders: K. Viswanath (DFCI) and D. Williams(HSPH). During the current project period, the goals of the Program were substantially revised to include new research foci including: 1) the individual and societal factors that predispose to cancer risk, 2) the science of dissemination and 3) an explicit focus on cancer disparities, all of which represent expanded and vibrant strengths within the Program. The expertise of the 49 members spans epidemiology, molecular epidemiology, behavioral science, communication science, intervention science, health policy and dissemination. In 2009, the Program received $19.7 million in cancer-relevant funding (total costs), which included over $11.9 million in NCI funding and $6.5 million in other federal, peer-reviewed funding. Attesting to the productivity and interactivity of the Program are the 903 publications authored by members of the Program during the project period (2006 to 2010), of which 15.5% were Intra-programmatic ,18% were inter-programmatic and 16% were inter-institutional collaborations.

Public Health Relevance

The Cancer Risk and Disparities Program seeks to identify the causes of increased risk of cancer, to design interventions to address these causes and to disseminate this knowledge effecfively into the community by advancing the methodologies of communication science and knowledge translafion. The Program is committed to reducing the incidence of cancer and its unequal distribution in the US population through its research and involvement in health and social policy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-47
Application #
8228290
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$92,996
Indirect Cost
$69,350
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :
Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8
Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52
Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8
Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504
Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96
McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534
Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201
Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 303 publications